Skip to content

MGUS/MM Awareness and Genetics Insights Campaign (MAGIC) Screening Study

Monoclonal Gammopathy of Undetermined Significance (MGUS) /Myeloma Awareness and Genetic Insights Campaign (MAGIC) Screening Study

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06472830
Acronym
MAGIC
Enrollment
1000
Registered
2024-06-25
Start date
2024-05-22
Completion date
2029-05-31
Last updated
2026-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Monoclonal Gammopathy of Undetermined Significance

Brief summary

This study is being done to screen adults for MGUS and to better understand the genetic and immune factors linked to this condition. Monoclonal gammopathy of undetermined significance or MGUS is a condition where an abnormal immune protein is found in the blood. MGUS is not cancer. In some people, it slowly develops into a blood cancer called multiple myeloma. MGUS occurs in people from all backgrounds. Researchers hope to use the information from this study to improve knowledge, early detection, and future care for everyone.

Detailed description

PRIMARY OBJECTIVE: I. To determine the prevalence of monoclonal gammopathies (MGUS, Smoldering and Multiple Myeloma) across ancestrally diverse populations in Minnesota, with prespecified, ancestry-informed analyses within East African, West African, Afro-Caribbean, and Non-Hispanic White groups. OUTLINE: This is an observational study. Participants undergo medical chart review and blood sample collection, as well as complete a questionnaire on study. Participants who test positive for MGUS are notified, along with their primary care physician, so that the necessary follow up and referral is provided as clinically indicated.

Interventions

OTHERNon-Interventional Study

Non-interventional study

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adults ≥ 40 years * Willing and able to review, understand, and provide consent before starting any study-specific procedures * Ability to complete questionnaire(s) by themselves or with assistance

Exclusion criteria

* Pregnant women

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of monoclonal gammopathies across ancestrally diverse populationsUp to 10 yearsScreen for monoclonal gammopathies using mass spectrometry to detect monoclonal proteins among people across ancestrally diverse populations in Minnesota, with prespecified, ancestry-informed analyses within East African, West African, Afro-Caribbean, and Non-Hispanic White groups.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJoselle M. Cook, M.B.B.S.

Mayo Clinic in Rochester

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 12, 2026